AKTX Stock Shoots 50% Higher To Head Toward Best Month In Nearly 11 Years – What’s Fueling This Super Rally?

Akari Therapeutics reported a Q2 2026 net loss of $4.8M, up from $1.9M a year earlier, and said it ended June 30, 2026 with $7.7M cash. The company raised about $8.6M gross proceeds (about $8.0M net) via private placement and warrant exercises. Akari is advancing AKTX-101 toward a planned mid-2027 Phase 1 start.

Akari Therapeutics Plc (AKTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Akari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload Platform AKTX-101 advancing through IND-enabling development activities toward planned initiation of P

SciSparc (SPRC) shares rose ~140% after its TSX Venture subsidiary received conditional approval to buy ~54% of private Israeli CliniQuantum for 56.6M NeuroThera shares (~$9.46M). Co-Diagnostics (CODX) gained ~53% for a third day amid Ebola PCR assay progress. Akari (AKTX) jumped ~38% on ASCO abstract acceptance and new KRAS-mutant synergy data; Outlook (OTLK) rose ~26% ahead of a June FDA resubmission.

ChangXin Memory Technologies (CXMT), a Chinese chipmaker, announced progress in memory chip design, causing a selloff in semiconductor stocks. Samsung, SK Hynix, and Micron shares dropped 7.4%, 10%, and 5% respectively. CXMT's market cap is around $520B, with a 10% global DRAM market share. The company's 4F² memory architecture aims to increase storage density, but its commercial success is uncertain.

Microsoft (MSFT) shares rose 1.0% to $546.74 on October 13. The company announced plans for Maia 300, an AI chip expected to increase throughput and efficiency. Microsoft projects up to seven times the throughput of Maia 200 and 40% more tokens per megawatt. The chip's impact on costs and earnings remains uncertain. MSFT shares trade 7.72% below GuruFocus's GF Value estimate of $592.48.

AbbVie presented Phase 3 AFFIRM study results showing subcutaneous SKYRIZI® (risankizumab-rzaa) achieved higher endoscopic remission and ulcer-free endoscopy rates in Crohn's disease patients vs. placebo. The data supports FDA approval for a new induction dosing regimen. SKYRIZI is already approved for other immune-mediated diseases.